Krystal Biotech - Decode DEB Sponsored Testing Program

Genetic testing available to patients residing in the United States, including Puerto Rico

Decode DEB

What is the Decode DEB program?

The Decode DEB sponsored testing program offers genetic testing for patients with suspected epidermolysis bullosa (EB) and qualifying family members.

Epidermolysis Bullosa (EB) is a clinically and genetically heterogeneous skin separation disorder. Based on the level of skin separation, it can be divided into four major subgroups: epidermolysis bullosa simplex (EBS), dystrophic epidermolysis bullosa (DEB), junctional epidermolysis bullosa (JEB), and Kindler Epidermolysis Bullosa (KEB).1

To learn more about DEB, visit: DebFacts.com/hcp

Test panel

This program offers testing with the Krystal Bio Decode DEB panel

  • icon-dna-strands-mintPolo

    Decode DEB 25 Gene Panel

    ATP2C1, CD151, CDSN, COL17A1, COL7A1, DSG1, DSP, DST, EXPH5, FERMT1, ITGA3, ITGA6, ITGB4, JUP, KLHL24, KRT1, KRT10, KRT14, KRT5, LAMA3, LAMB3, LAMC2, PKP1, PLEC, SERPINB8

How to order

Our easy-to-order panels align with professional guidelines, making your potential next steps clearer.

  • Step 1 duotone icon

    Step 1

    Discuss testing and get consent from the eligible patient as set forth in Labcorp Genetics' Informed Consent for Genetic Testing. Place your order via our convenient online portal or paper requisition form.

  • Step 2 duotone icon

    Step 2

    Collect your patient's specimen using an Invitae collection kit and ensure the collection container is labeled completely with the patient's name, date of birth, sample collection date, and/or any additional identifiers such as an MRN. Use the pre-paid label provided to ship the sample to the lab.

  • Genetic testing expert - Invitae icon

    Step 3

    Results will be posted to the Invitae provider portal in 10-21 days from the time the sample is received and begins processing. Access resources to guide your discussion with the patient about their results. Invitae's Clinical Consult team of genetic counselors are available to assist. You may contact them at 800-436-3037 or clinconsult@invitae.com.

Next steps and additional services

Clinical features

Epidermolysis Bullosa Simplex (EBS)

EBS is the most common form and is characterized by fragility of the skin that results in blistering and erosions within the basal keratinocytes.1 Clinical features range from localized blistering on the hands and feet to severe, widespread involvement that can include nail dystrophy and thickened skin on the palms and soles. While EBS is most commonly inherited in an autosomal dominant manner, in specific recessive subtypes, the disease may present with serious systemic complications such as muscular dystrophy, cardiomyopathy, or pyloric atresia.2

Dystrophic Epidermolysis Bullosa

In DEB, skin cleavage occurs below the lamina densa of the basement membrane zone, occurring at the level of the anchoring fibrils.1 The disorder is caused by mutations in the COL7A1 gene and can be inherited in either an autosomal dominant or autosomal recessive pattern. The severe recessive type can lead to debilitating complications such as fused fingers (pseudosyndactyly), joint contractures, esophageal strictures, and an increased risk of squamous cell carcinoma. In contrast, dominant and intermediate recessive forms typically present with milder symptoms, where blistering and scarring are more localized to the hands, feet, knees, and elbows.3

Junctional Epidermolysis Bullosa

JEB is an autosomal recessive disorder where skin cleavage occurs through the lamina lucida of the basement membrane zone.1 It is generally less common than the simplex or dystrophic types and is characterized by extreme fragility of the skin and mucous membranes, causing blisters to form after minimal trauma. In its generalized severe form, pervasive blistering is present from birth, and affected individuals often develop exuberant granulation tissue around the oral and nasal cavities. The generalized intermediate form typically presents with more localized blistering on the hands, feet, and knees, sometimes with associated renal or ureteral involvement. Additional common clinical features across subtypes include nail dystrophy, dental enamel defects, and scarring alopecia.4

Kindler Epidermolysis Bullosa

KEB (formerly Kindler syndrome) is a rare autosomal recessive disorder with multiple levels of skin cleavage caused by mutations in the FERMT1 gene.1 Clinical features typically begin at birth with blistering of the hands and feet, which later evolves into diffuse skin atrophy, photosensitivity, and poikiloderma (mottled skin pigmentation). Mucosal involvement is also common and can lead to serious complications such as gingivitis, periodontitis, and strictures in the esophagus or urinary tract. Long-term, patients are at a significantly increased risk for developing aggressive squamous cell carcinomas, particularly in mucosal areas.5

About Krystal Biotech
Krystal's mission is to develop and deliver genetic medicines to patients using redosable gene therapies for the treatment of severe, life-threatening or rare diseases that have limited or no approved therapies.
References

  1. Has et al. 2020. PubMed ID: 32017015
  2. So et al. 2022. PubMed ID: 20301543
  3. Lucky et al. 2025. PubMed ID: 20301481
  4. Pfendner et al. 2018. PubMed ID: PMID: 20301304
  5. Youssefian et al. 2022. PubMed ID: 26937547

    Disclaimer: This is a sponsored testing program. While third parties and commercial organizations may provide financial support for this program, tests and services are performed by Labcorp Genetics. Healthcare professionals must confirm that patients meet certain criteria to use the program. Third parties and commercial organizations may receive de-identified (pseudonymized) patient data from this program, but at no time would they receive patient identifiable information. Third parties and commercial organizations may receive contact information for healthcare professionals who use this program. Genetic testing and counseling are available in the US. Healthcare professionals and patients who participate in this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use or support any other products or services from Labcorp Genetics or from third parties or commercial organizations.